Literature DB >> 2108997

Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.

P C Fuchs1, R N Jones, A L Barry.   

Abstract

Five hundred gram-positive clinical bacterial isolates were tested for susceptibility to mupirocin by broth microdilution and disk diffusion methods (5- and 10-micrograms disks). All but 1 of 330 staphylococci (including 100 oxacillin-resistant Staphylococcus aureus) were susceptible to less than or equal to 1.0 micrograms of mupirocin per ml. With a susceptible MIC breakpoint of less than or equal to 2.0 micrograms/ml, the corresponding zone diameter breakpoints were greater than or equal to 14 mm for 5-micrograms disks and greater than or equal to 16 mm for 10-micrograms disks. With either disk potency, susceptible staphylococci were effectively separated from more resistant gram-positive species such as the enterococci and gram-positive bacilli.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108997      PMCID: PMC269673          DOI: 10.1128/jcm.28.3.608-609.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

2.  Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid.

Authors:  J E Dacre; A M Emmerson; E A Jenner
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

3.  Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens.

Authors:  A T Fuller; G Mellows; M Woolford; G T Banks; K D Barrow; E B Chain
Journal:  Nature       Date:  1971-12-17       Impact factor: 49.962

4.  Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus burn wound infection.

Authors:  H Rode; D Hanslo; P M de Wet; A J Millar; S Cywes
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Nasal carriage of Staphylococcus aureus treated with topical mupirocin (pseudomonic acid) in a children's hospital.

Authors:  U Frank; W Lenz; E Damrath; I Kappstein; F D Daschner
Journal:  J Hosp Infect       Date:  1989-02       Impact factor: 3.926

6.  In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

7.  Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.

Authors:  R Sutherland; R J Boon; K E Griffin; P J Masters; B Slocombe; A R White
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

  7 in total
  22 in total

1.  Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples.

Authors:  Fernando Chaves; Jesus García-Martínez; Sonia de Miguel; Joaquín R Otero
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Staphylococcus haemolyticus as an important hospital pathogen and carrier of methicillin resistance genes.

Authors:  E M Barros; H Ceotto; M C F Bastos; K R N Dos Santos; M Giambiagi-Demarval
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

3.  Clonal dissemination and mupA gene polymorphism of mupirocin-resistant Staphylococcus aureus isolates from long-term-care facilities in South Korea.

Authors:  Jae Il Yoo; Eun Shim Shin; Jeong Ok Cha; Jeom Kyu Lee; Young Hee Jung; Kyeong Min Lee; Bong Su Kim; Yeong Seon Lee
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Genetic diversity of methicillin-resistant Staphylococcus aureus in a tertiary hospital in The Netherlands between 2002 and 2006.

Authors:  E Nulens; E E Stobberingh; E Smeets; H van Dessel; M A Welling; S Sebastian; F H van Tiel; P S Beisser; R H Deurenberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

5.  Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

Authors:  J E Finlay; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in Staphylococcus aureus.

Authors:  Jana M Swenson; Betty Wong; Andrew E Simor; Richard B Thomson; Mary Jane Ferraro; Dwight J Hardy; Janet Hindler; James Jorgensen; L Barth Reller; Maria Traczewski; Linda K McDougal; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-05-05       Impact factor: 5.948

7.  In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Authors:  Mark S Rouse; Margalida Rotger; Kerryl E Piper; James M Steckelberg; Matthew Scholz; Jeffrey Andrews; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Detection and characterization of mupirocin resistance in Staphylococcus aureus.

Authors:  D A Janssen; L T Zarins; D R Schaberg; S F Bradley; M S Terpenning; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital.

Authors:  M C Layton; J E Patterson
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Characteristics of Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Strains Isolated from Skin and Soft-Tissue Infections in Uruguay.

Authors:  Lorena Pardo; Virginia Machado; Marta Mollerach; María Inés Mota; Lorena P N Tuchscherr; Pilar Gadea; Noella Gardella; Daniel O Sordelli; Magdalena Vola; Felipe Schelotto; Gustavo Varela
Journal:  Int J Microbiol       Date:  2009-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.